Skip to main content
Click Here For COVID-19 Studies
Home
Clinical Trials Office Register as a Researcher Log In
348 Studies Now Enrolling
 Menu
Home How It Works Resources Join RecruitMe

Search

Reset

Status

  • Closed (4)

Medical Condition

  • Show all (226)
  • Addiction (1)
  • Allergy, Asthma, & Immunology (3)
  • Autoimmune Disorders (4)
  • Cancer (160)
    • (-) Breast Cancer (3)
    • Gynecologic Cancer (1)
    • Head and Neck Cancer (1)
    • (-) Leukemia (1)
    • Lung Cancer (62)
    • Pancreatic Cancer (1)
    • Prostate Cancer (1)
    • Skin Cancer (3)
    • Solid Tumors (10)
    • Uveal Melanoma (1)
  • COVID-19 (Coronavirus) (3)
  • Healthy Volunteers (8)
  • Heart Disease (4)
  • Liver Disease (2)
  • Lung Disease (32)
  • Neurological Disorders (1)
  • Pediatrics (5)
  • Surgery (1)
  • Transplant (2)
Displaying 1 - 4 of 4

A Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy

Condition: Cancer / Leukemia
Investigator: Ran Reshef, MD
Status: Closed
Patients who will be receiving immune effector cell (IEC) therapy for the treatment of their cancer (leukemia) are being asked to participate in this study. IEC can produce a harmful side effect called Cytokine Release Syndrome (CRS). CRS involves a release of a large amount of proteins into the bloodstream. This may cause changes in blood pressure and…
Read More

Study of Imprime PGG and Pembrolizumab (Keytruda) in Patients with Metastatic Breast Cancer (mBCA)

Condition: Cancer / Breast Cancer
Investigator: Julia McGuinness, MD
Status: Closed
The purpose of this study is to find out, good and/or bad, the effects of the investigational drug, Imprime PGG, when given together with pembrolizumab (also known as Keytruda, a type of checkpoint inhibitor) in the treatment of your type of cancer. Checkpoint inhibitors are a type of immunotherapy that block immune checkpoint proteins from binding with…
Read More

Olaparib With or Without Atezolizumab in Treating Patients With Locally Advanced or Metastatic Non-HER2-Positive Breast Cancer

Condition: Cancer / Breast Cancer
Investigator: Meghna Trivedi, MD
Status: Closed
The purpose of this study is to compare any good and bad effects of using olaparib and atezolizumab in combination compared to olaparib alone. The use of olaparib alone or in combination with atezolizumab could shrink your cancer but could also cause side effects. This study will allow the researchers to know whether the combination approach is better, the…
Read More

TrACER: Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER) for Patients Receiving Chemotherapy

Condition: Cancer / Breast Cancer
Investigator: Dawn Hershman, MD
Status: Closed
This randomized clinical trial studies prophylactic colony stimulating factor management in patients with breast, colorectal or non-small cell lung cancer receiving chemotherapy and with risk of developing febrile neutropenia. Patients receiving chemotherapy may develop febrile neutropenia. Febrile neutropenia is a condition…
Read More
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE
COMPLIANCE
Compliance Hotline Compliance Program
RESOURCES
Contact RecruitMe Terms of Use Privacy Policy ©2025 Columbia University
SCHOOLS
Vagelos College of Physicians and Surgeons Mailman School of Public Health School of Nursing College of Dental Medicine Graduate School of Arts and Science